Skip to main content
. Author manuscript; available in PMC: 2023 Mar 17.
Published in final edited form as: Ophthalmology. 2015 May 9;122(7):1426–1437. doi: 10.1016/j.ophtha.2015.04.006

Figure 3.

Figure 3.

Graphs showing long-term visual outcomes in patients with macular edema resulting from retinal vein occlusion treated with a combination of ranibizumab and scatter and grid laser photocoagulation versus ranibizumab alone. Patients were re-randomized at week 24 to pro re nata (PRN) ranibizumab plus scatter and grid laser photocoagulation (laser + RBZ) or PRN ranibizumab alone RBZ alone. The graphs show the mean (±standard error of the mean) change from week 24 in best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study letter score at all time points through week 144 in patients with (A) macular edema resulting from branch retinal vein occlusion (BRVO) or (B) central retinal vein occlusion (CRVO). There was no significant difference between laser plus ranibizumab and ranibizumab only groups at week 144 in patients with BRVO or CRVO.